About us
We are one of five Proteome Characterization Centers (PCCs) funded by the National Cancer Institute (NCI). The primary goal of the PCCs is to comprehensively characterize tumors and biospecimens in order to systematically identify, prioritize, and verify cancer-related proteins for the development of biomarkers. The proteomic technologies for cancer proteome characterization include protein microarray, immunoassays, and mass-spectrometry-based methods. The aim is to bridge genomic and proteomic discoveries to medicine using proteomic technologies. more information...
History
The Center for Biomarker Discovery and Translation is a division of the Pathology Department at The Johns Hopkins University School of Medicine in Baltimore, Maryland. It was founded as the Center for Biomarker Discovery in 2000 by Dr. Daniel Chan, and became the Center for Biomarker Discovery & Translation in 2010. more information...
Research
Our research interests are centered on understanding functions of proteins and protein modifications using high-throughput proteomic technologies. Currently, projects in the lab focus on understanding structures and functions of proteins and protein glycosylation in biology and human diseases. Researchers in the group developed integrated proteomic, glycoproteomic, and glycomic technologies for comprehensive glycoprotein characterization. These technologies enable the identification and quantification of glycoproteins, glycosites, glycans associated with each glycosite and their occupancies. The group participates in several research programs including Early Detection Research Network (EDRN), Clinical Proteomic Tumor Analysis Consortium (CPTAC), and Programs of Excellence in Glycosciences (PEG).
Key Publications
Glycoproteomic Technologies and Applications
Glycosite Analysis
Solid-phase extraction of N-linked glycopeptides
Y Tian, Y Zhou, S Elliott, R Aebersold, H Zhang, 2007
Glycomic Analysis
Simultaneous quantification of N-and O-glycans using a solid-phase method
S Yang, Y Hu, L Sokoll, H Zhang, 2017
Glycomic analysis using glycoprotein immobilization for glycan extraction
S Yang, Y Li, P Shah, H Zhang, 2013
S Yang, S Toghi Eshghi, H Chiu, DL DeVoe, H Zhang, 2013
Site-specific Analysis of Glycosylation
W Yang, P Shah, S Toghi Eshghi, S Yang, S Sun, M Ao, A Rubin,JB Jackson and H Zhang, 2014
S Sun, P Shah, ST Eshghi, W Yang, N Trikannad, S Yang, L Chen,P Aiyetan, N Höti, Z Zhang, D W Chan & H Zhang, 2016
Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides
Y Hu, P Shah, D J Clark, M Ao, H Zhang, 2018
P Shah, X Wang, W Yang, ST Eshghi, S Sun, N Hoti, L Chen, S Yang,J Pasay, A Rubi and H Zhang, 2015
W Yang, P Shah, Y Hu, S Toghi Eshghi, S Sun, Y Liu, H Zhang, 2017
Proteomic Technologies and Applications
Proteogenomics connects somatic mutations to signalling in breast cancer
P Mertins, et.al., 2016
Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
H Zhang, et.al.,2016
CPTAC Assay Portal: a repository of targeted proteomic assays
JR Whiteaker, et.al., 2014
Proteogenomic characterization of human colon and rectal cancer
B Zhang, et.al., 2014
Current Projects & Grants
Proteome Characterization Center: a genoproteomics pipeline for cancer biomarkers
U24CA160036
NIH/NCI
PI: Chan D, Zhang H, Zhang Z
Role: Co-Principal Investigator
This is a center in Clinical Proteomic Tumor Analysis Consortium (CPTAC). The major goal of this Center is the proteomic characterization of cancer tissues and plasma samples with genomic data to not only verify the genomic alterations at the protein level but also allow for the analysis of unique features that are inherent to proteins including post-translational modification.
Center members on CPTAC project:
Ph.D., Post-doctoral Fellow
Ph.D., Post-doctoral Fellow
Mechanism and anti-cancer activity of SCFA-hexosamine analogs
R01CA112314
NIH/NCI
PI: Yarema, Kevin
Role: Co-investigator
The goal of the parent grant to this project is to develop novel sugar-based cancer drugs to treat metastatic cancer.
Glycoconjugates and cardiovascular disease
P01HL107153
NIH/NHLBI
PI: Hart, Gerald
Role: Principal Investigator for project #4
Co-Principal Investigator (with Van Eyk) for mass spectrometry core
This is a center of Programs of Excellence in Glycosciences (PEG). The central theme of this center is the roles of both extracellular and intracellular glycoconjugates in the mechanisms protecting the heart or leading to atherosclerosis and cardiomyopathies, culminating in myocardial infarction and heart failure.
Clinical and Analytical Validation of Cancer Biomarkers
U24CA115102
NIH/NCI
PI: Chan, Daniel
Role: Co-investigator/developmental project leader
Notes: This is a biomarker reference laboratory (BRL) of the Early Detection Research Network (EDRN). The major goal of this project is to conduct analytical and clinical validation studies of biomarkers.
Center members on EDRN project:
Infectious Disease
amfAR
PI: Yang, Weiming
Role: Principal Investigator
Deciphering the Latency‐associated Sugar‐code to Detect and Eliminate HIV Latent Reservoir.
Center members on Infectious Disease project:
Johns Hopkins proteomic innovation center in heart failure
HHSN268201000032C (N01-HV-00240)
NIH/NHLBI
PI: Van Eyk, Jennifer
Role: Co-investigator
This is a center of NHLBI Proteomics Centers. The goal of this project is to develop and apply innovative mass spectrometry based PTM capture methods in heart failure. In particular, my project will focus on glycoproteome tools in both tissue and blood samples.